Albshesh, AhmadTaylor, JoshuaSavarino, Edoardo V.Truyens, MarieArmuzzi, AlessandroRibaldone, Davide G.Shitrit, Ariella Bar-GilFibelman, MorineMolander, PauliinaLiefferinckx, ClaireNancey, StephaneKorani, MohamedRutka, MariannBarreiro de Acosta, ManuelDomislovic, ViktorSuris, GerardEriksson, CarlAlves, CatarinaMpitouli, AfroditiDi Jiang, CarolineTepeš, KatjaColetta, MarinaFoteinogiannopoulou, KalliopiGisbert, Javier P.Amir-Barak, HadarAttauabi, MohamedSeidelin, JakobAfif, WaqqasMarinelli, CarlaLobatón, TrianaPugliese, DanielaMaharshak, NitsanCremer, AnnelineLimdi, Jimmy K.Molnár, TamásOtero Alvarin, BorjaKrznaric, ZeljkoMagro, FernandoKarmiris, KonstantinosRaine, TimDrobne, DavidKoutroubakis, IoannisChaparro, MariaYanai, HenitBurisch, JohanKopylov, Uri2021-07-222021-07-222021-06-292077-0383https://hdl.handle.net/2445/179326Background: Multiple studies have described the effectiveness of ustekinumab (UST) and vedolizumab (VDZ) in patients with Crohn's disease (CD) failing anti- Tumor necrosis factors (TNFs); however, the effectiveness of VDZ or UST as a third-class biologic has not yet been described. Aims and methods: In this retrospective multicenter cohort study, we aimed to investigate the effectiveness of VDZ and UST as a third-class biologic in patients with CD. Results: Two-hundred and four patients were included; 156/204 (76%) patients received VDZ as a second- and UST as a third-class therapy (group A); the remaining 48/204 (24%) patients received UST as a second- and VDZ as a third-class therapy (group B). At week 16-22, 87/156 (55.5%) patients and 27/48 (56.2%) in groups A and B, respectively, responded to treatment (p = 0.9); 41/156 (26.2%) and 15/48 (31.2%) were in clinical remission (p = 0.5). At week 52; 89/103 (86%) patients and 25/29 (86.2%) of the patients with available data had responded to third-class treatment in groups A and B, respectively (p = 0.9); 31/103 (30%) and 47/29 (24.1%) were in clinical remission (p = 0.5). Conclusion: Third-class biological therapy was effective in more than half of the patients with CD. No differences in effectiveness were detected between the use of VDZ and UST as a third-class agent.13 p.application/pdfengcc by (c) Albshesh, Ahmad et al., 2021http://creativecommons.org/licenses/by/3.0/es/Malaltia de CrohnMalalties inflamatòries intestinalsInflammatory bowel diseasesCrohn's diseaseinfo:eu-repo/semantics/article2021-07-22info:eu-repo/semantics/openAccess34209880